Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 10/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.42 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.41 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13851544 | 0.91 | ITGA4 (0.50) | SLC6A9ITGB1ITGA5ITGA4ITGB7 | |
| SCHEMBL13851498 | 0.89 | ITGA4 (0.44) | GAAITGB1ITGA5ITGA4ITGB7 | |
| SCHEMBL3819070 | 0.86 | ITGB1 (0.49) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL13851714 | 0.84 | ITGA4 (0.48) | ITGB1ITGA4ITGB7CTSCCCR1 | |
| SCHEMBL8242092 | 0.82 | CYP2D6 (0.56) | GAAITGB1ITGA5ITGA4ITGB7 | |
| SCHEMBL3824395 | 0.81 | ITGB1 (0.48) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL4152850 | 0.81 | ITGA4 (0.45) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL3823897 | 0.80 | ITGA4 (0.52) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL13851542 | 0.76 | MEN1 (0.50) | GAAITGB1ITGA5ITGA4ITGB7 | |
| SCHEMBL13851720 | 0.76 | ITGB1 (0.52) | ITGB1ITGA4ITGB7ITGA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137601-A1 | L-Phenylalanine Derivatives | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| WO-2007060408-A2 | L-PHENYLALANINE DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137601-A1 | L-Phenylalanine Derivatives | ITGB5, ITGB1, ITGA2B | SLC6A9 3663/4885GAA 2385/4885ITGB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.